{"title":"FDA officials asked to step down after contentious Alzheimer’s drug approval","link":"https://arstechnica.com/?p=1774338","date":1623954835000,"content":"<div>\n<figure><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2019/05/GettyImages-496532228-800x512.jpg\" /><p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2019/05/GettyImages-496532228.jpg\">Enlarge</a> <span>/</span> The Food and Drug Administration headquarters in White Oak, Maryland. (credit: <a href=\"https://www.gettyimages.com/detail/news-photo/the-outside-of-the-food-and-drug-administration-news-photo/496532228?adppopup=true\">Getty | Congressional Quarterly</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p>A leading advocacy and watchdog group is <a href=\"https://www.citizen.org/news/letter-acting-fda-commissioner-woodcock-other-top-officials-must-resign-following-indefensible-aducanumab-approval/\">calling for the ouster of three top officials at the Food and Drug Administration</a>—including its acting commissioner—after the regulator issued a highly contentious approval last week of the unproven and now highly priced Alzheimer’s drug Aduhelm (generic name: aducanumab).</p>\n<p>The call for fresh FDA leadership comes atop a chorus of harsh criticism over the decision, which outside researchers and industry experts have called <a href=\"https://arstechnica.com/science/2021/06/a-disgraceful-decision-researchers-blast-fda-for-approving-alzheimers-drug/\">“disgraceful” and “dangerous,”</a> among other things.</p>\n<p>Since Aduhelm’s approval was announced June 7, <a href=\"https://arstechnica.com/science/2021/06/three-experts-resign-as-fda-advisors-over-approval-of-alzheimers-drug/\">three expert advisers to the FDA have resigned in protest</a>, with one calling the decision “probably the worst drug-approval decision in recent US history.” The three experts were part of an 11-member advisory committee that reviewed the clinical data for the Alzheimer’s drug last November and voted nearly unanimously <em>against</em> approval (10 voted against, 1 voted “uncertain”).</p></div><p><a href=\"https://arstechnica.com/?p=1774338#p3\">Read 8 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1774338&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"b007348d608011e7d9e1d83cd46fbf8d6f3da7788f86229c92b8b112a696490e","category":"Tech"}